Globus Medical Inc. Class A Common Stock vs Companhia de saneamento Basico Do Estado De Sao Paulo - Sabesp American Depositary Shares (Each repstg 250 Common Shares) — how do they compare? Globus Medical Inc. Class A Common Stock trades at $76.58 (market cap $10.25B), while Companhia de saneamento Basico Do Estado De Sao Paulo - Sabesp American Depositary Shares (Each repstg 250 Common Shares) trades at $6.29 (market cap $22.94B). The key difference: Companhia de saneamento Basico Do Estado De Sao Paulo - Sabesp American Depositary Shares (Each repstg 250 Common Shares) is far larger — about 2.2× Globus Medical Inc. Class A Common Stock's market cap, and Companhia de saneamento Basico Do Estado De Sao Paulo - Sabesp American Depositary Shares (Each repstg 250 Common Shares) pays a 0.52% dividend while Globus Medical Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Globus Medical Inc. Class A Common Stock for 0 Days and Companhia de saneamento Basico Do Estado De Sao Paulo - Sabesp American Depositary Shares (Each repstg 250 Common Shares) for 1 Days on average.
| GMED | SBS | |
|---|---|---|
Market Cap | $10.25B | $22.94B |
Volume | 1,108,124 | 9,400,047 |
Sector | Health | Utilities |
52-Week High | $96.82 | $7.08 |
52-Week Low | $58.33 | $4.46 |
Typical Hold Time | 0 Days | 1 Days |
Enterprise Value | $9.76B | $29.80B |
Dividend Yield | — | 0.52% |
Signals from Pluang's Aura AI — not financial advice
Globus Medical (GMED) trades at $76.32, showing minimal daily movement with a 0.1% gain. The stock demonstrates strong fundamental performance with consistent earnings beats in recent quarters and robust profitability metrics including 68.55% gross margins and 17.03% net income margins. Technical indicators suggest neutral positioning near key support at $73 with resistance at $74. Recent developments include new product showcases at industry conferences and upcoming Q3 earnings release.
GMED presents a compelling investment case with strong analyst support (72% buy rating) and 25% upside to consensus target of $95.13. The company maintains solid revenue growth trajectory and debt-free balance sheet, though investors should monitor competitive pressures in medical devices and potential margin compression as revenue scales. Near-term catalysts include Q3 earnings results expected November 5, 2026.
SBS trades at $6.45, down 4.16% today, with a P/E of 13.54 and a net income margin of 19.71%. Recent earnings showed a Q2 2026 miss after two prior beats. Technical indicators are mixed, with a bullish moving average signal but bearish oscillators. The company reported 2025 revenue of $38.09B and net income of $8.46B, though 2026 projections indicate a slight decline in profit margin to 19.71%.
The outlook is cautious; while valuation metrics appear reasonable and profitability is strong, recent earnings volatility and a negative net cash flow projection for 2026 pose risks. Analyst sentiment is mixed with a 'Hold' consensus, suggesting limited near-term upside potential amid operational headwinds.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Globus Medical, Inc. develops and manufactures medical devices for treating musculoskeletal disorders, including spine, orthopedic trauma, and neurosurgical products. It operates in US and internationally, serving surgeons and healthcare providers.
Read more on GMED →Sabesp provides water supply and sewage services in the Brazilian state of São Paulo. Its shares trade in Brazil as SBSP3 and in the U.S. as NYSE-listed ADSs under SBS.
Read more on SBS →